Results from published systematic reviews and meta-analyses also have been equivocal, with statistically mixed results of various outcome measures. In a 2009 Cochrane systematic review of 5 studies published before 2005, Askie et al48 concluded that a policy of unrestricted or unmonitored oxygen therapy has potential harms, particularly ROP, without clear benefits compared with a restricted oxygen use protocol. In a 2014 meta-analysis of the Surfactant, Positive Pressure, and Pulse Oximetry Randomized Trial (SUPPORT), 3 Benefits of Oxygen Saturation Targeting (BOOST) studies, and Canadian Oxygen Trial (COT), Saugstad and Aune49 found that lower oxygen saturation target levels were associated with more deaths and more incidences of necrotizing enterocolitis, but less ROP, than higher target levels. Manja et al50 also reviewed these 5 studies and found that the lower oxygen saturation target group had higher mortality before hospital discharge and a higher incidence of necrotizing enterocolitis than the higher oxygen saturation group, but no difference was observed for neurodevelopmental outcomes, ROP, or hearing loss. However, significant outcomes were associated with a low level of confidence; thus, the investigators concluded that the optimal target oxygen saturation in extremely preterm infants remains uncertain.50
The most recent pooled analysis included data from 2 BOOST II studies (correcting an oximeter calibration–algorithm artifact); investigators found that an oxygen saturation target range of 85% to 89% was associated with a significant increase in risk of the combined outcome of death or disability and the outcome of death alone compared with a higher target range of 91% to 95%.51 Variations in study populations across the 5 major studies of the Neonatal Oxygen Prospective Meta-analysis Collaboration, of which the BOOST II studies were a part, may account for differences in mortality rates51 and therefore limit the ability to determine statistical significance consistently for these differences. Moreover, achieved versus intended oxygen saturation was highly variable in these studies and may have influenced results.52 However, taken together, these 5 studies suggest that lower oxygen saturation levels may increase the risk of death; thus, targeting oxygen saturation at 91% to 95% may be safer.51 , 52 These higher target ranges must be monitored closely and should not exceed 95% at the risk of developing disorders associated with oxidative stress.3 , 52 Importantly, the oxygen saturation target range may vary with advancing gestational age and postnatal age.46
In 2003, the Cedars-Sinai Medical Center and UCLA School of Medicine published a protocol for the management of supplemental oxygen use with oxygen saturation target levels of 85% to 93% and setting low and high alarms, respectively.30 Implementation of this protocol has been associated with a significantly shorter length of hospital stay, decreased need for supplemental oxygen and steroids for chronic lung disease, and a lower rate of ROP in very low birth-weight infants.30 , 53 , 54 In another study targeting oxygen saturation between 88% and 92% with alarm limits of 85% and 95%, respectively, the incidence of chronic lung disease was significantly reduced (P = .001) and fewer infants were discharged from the hospital with oxygen therapy than those with less restrictive oxygen protocols that were previously used.55
1. Wyckoff MH, Aziz K, Escobedo MB, et al Part 13: neonatal resuscitation
: 2015 American Heart Association Guidelines update for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2015;132:S543–S560.
2. Maltepe E, Saugstad OD. Oxygen
in health and disease: regulation of oxygen
homeostasis—clinical implications. Pediatr Res. 2009;65:261–268.
3. Sola A, Saldeno YP, Favareto V. Clinical practices in neonatal oxygenation: where have we failed? What can we do? J Perinatol. 2008;28(suppl 1):S28–S34.
4. Castillo A, Sola A, Baquero H, et al Pulse oxygen saturation
levels and arterial oxygen
tension values in newborns receiving oxygen
therapy in the neonatal intensive care unit: is 85% to 93% an acceptable range? Pediatrics. 2008;121:882–889.
5. Greenspan JS, Goldsmith JP. Oxygen
therapy in preterm infants: hitting the target. Pediatrics. 2006;118:1740–1741.
6. Kattwinkel J, Perlman JM, Aziz K, et al Neonatal resuscitation
: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Pediatrics. 2010;126:e1400–e1413.
7. Lakshminrusimha S. The pulmonary circulation in neonatal respiratory failure. Clin Perinatol. 2012;39:655–683.
8. Rudolph AM. The changes in the circulation after birth. Their importance in congenital heart disease. Circulation. 1970;41:343–359.
9. Dawes GS, Mott JC, Widdicombe JG, Wyatt DG. Changes in the lungs of the new-born lamb. J Physiol. 1953;121:141–162.
10. Abman SH, Chatfield BA, Hall SL, McMurtry IF. Role of endothelium-derived relaxing factor during transition of pulmonary circulation at birth. Am J Physiol. 1990;259:H1921–H1927.
11. Steinhorn RH. Diagnosis and treatment of pulmonary hypertension in infancy. Early Hum Dev. 2013;89:865–874.
12. Deuber C, Terhaar M. Hyperoxia
in very preterm infants: a systematic review of the literature. J Perinat Neonatal Nurs. 2011;25:268–274.
13. Kulkarni AC, Kuppusamy P, Parinandi N. Oxygen
, the lead actor in the pathophysiologic drama: enactment of the trinity of normoxia, hypoxia
, and hyperoxia
in disease and therapy. Antioxid Redox Signal. 2007;9:1717–1730.
14. Winslow RM. Oxygen
: the poison is in the dose. Transfusion (Paris). 2013;53:424–437.
16. Walsh BK, Brooks TM, Grenier BM. Oxygen
therapy in the neonatal care environment. Respir Care. 2009;54:1193–1202.
17. O'Donovan DJ, Fernandes CJ. Free radicals and diseases in premature infants. Antioxid Redox Signal. 2004;6:169–176.
18. Finer N, Leone T. Oxygen saturation
monitoring for the preterm infant: the evidence basis for current practice. Pediatr Res. 2009;65:375–380.
19. Zhou Y, Wang Q, Evers BM, Chung DH. Signal transduction pathways involved in oxidative stress-induced intestinal epithelial cell apoptosis. Pediatr Res. 2005;58:1192–1197.
20. Sears NC, Sears JE. Oxygen
and retinopathy of prematurity
. Int Ophthalmol Clin. 2011;51:17–31.
21. Anderson WR, Strickland MB, Tsai SH, Haglin JJ. Light microscopic and ultrastructural study of the adverse effects of oxygen
therapy on the neonate
lung. Am J Pathol. 1973;73:327–348.
22. Northway WH Jr, Rosan RC. Radiographic features of pulmonary oxygen
toxicity in the newborn: bronchopulmonary dysplasia. Radiology. 1968;91:49–58.
23. Jobe AH, Kallapur SG. Long term consequences of oxygen
therapy in the neonatal period. Semin Fetal Neonatal Med. 2010;15:230–235.
24. Zia MT, Csiszar A, Labinskyy N, et al Oxidative-nitrosative stress in a rabbit pup model of germinal matrix hemorrhage: role of NAD(P)H oxidase. Stroke. 2009;40:2191–2198.
25. Tin W, Gupta S. Optimum oxygen
therapy in preterm babies. Arch Dis Child Fetal Neonatal Ed. 2007;92:F143–F147.
26. Spector LG, Klebanoff MA, Feusner JH, Georgieff MK, Ross JA. Childhood cancer following neonatal oxygen
supplementation. J Pediatr. 2005;147:27–31.
27. Naumburg E, Bellocco R, Cnattingius S, Jonzon A, Ekbom A. Supplementary oxygen
and risk of childhood lymphatic leukaemia. Acta Paediatr. 2002;91:1328–1333.
28. Cnattingius S, Zack MM, Ekbom A, et al Prenatal and neonatal risk factors for childhood lymphatic leukemia. J Natl Cancer Inst. 1995;87:908–914.
29. Anderson CG, Benitz WE, Madan A. Retinopathy of prematurity
and pulse oximetry: a national survey of recent practices. J Perinatol. 2004;24:164–168.
30. Chow LC, Wright KW, Sola A. Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity
in very low birth weight infants? Pediatrics. 2003;111:339–345.
31. Laughon M, Allred EN, Bose C, et al Patterns of respiratory disease during the first 2 postnatal weeks in extremely premature infants. Pediatrics. 2009;123:1124–1131.
32. Ment LR, Aden U, Lin A, et al Gene-environment interactions in severe intraventricular hemorrhage of preterm neonates. Pediatr Res. 2014;75:241–250.
33. Haynes RL, Folkerth RD, Keefe RJ, et al Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol. 2003;62:441–450.
34. Resuscitation and stabilization of babies born preterm. In: Weiner GM, Zaichkin J, eds. Textbook of Neonatal Resuscitation
. 7th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2016:225–241.
35. Saugstad OD. Why are we still using oxygen
to resuscitate term infants? J Perinatol. 2010;30(suppl):S46–S50.
36. Lakshminrusimha S, Russell JA, Steinhorn RH, et al Pulmonary arterial contractility in neonatal lambs increases with 100% oxygen
resuscitation. Pediatr Res. 2006;59:137–141.
37. Lakshminrusimha S, Steinhorn RH, Wedgwood S, et al Pulmonary hemodynamics and vascular reactivity in asphyxiated term lambs resuscitated with 21 and 100% oxygen
. J Appl Physiol. 2011;111:1441–1447.
38. Farrow KN, Lakshminrusimha S, Reda WJ, et al Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2008;295:L979–L987.
39. Saugstad OD, Ramji S, Soll RF, Vento M. Resuscitation of newborn infants with 21% or 100% oxygen
: an updated systematic review and meta-analysis. Neonatology. 2008;94:176–182.
40. Stola A, Schulman J, Perlman J. Initiating delivery room stabilization/resuscitation in very low birth weight (VLBW) infants with an FiO(2) less than 100% is feasible. J Perinatol. 2009;29:548–552.
41. Vento M, Sastre J, Asensi MA, Vina J. Room-air resuscitation causes less damage to heart and kidney than 100% oxygen
. Am J Respir Crit Care Med. 2005;172:1393–1398.
42. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen
-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959–967.
43. Carlo WA, Finer NN, Walsh MC, et al Target ranges of oxygen saturation
in extremely preterm infants. N Engl J Med. 2010;362:1959–1969.
44. Darlow BA, Marschner SL, Donoghoe M, et al Randomized controlled trial of oxygen saturation
targets in very preterm infants: two year outcomes. J Pediatr. 2014;165:30–35.
45. Schmidt B, Whyte RK, Asztalos EV, et al Effects of targeting higher vs lower arterial oxygen
saturations on death or disability in extremely preterm infants: a randomized clinical trial. JAMA. 2013;309:2111–2120.
46. Stenson BJ, Tarnow-Mordi WO, Darlow BA, et al Oxygen saturation
and outcomes in preterm infants. N Engl J Med. 2013;368:2094–2104.
47. Vaucher YE, Peralta-Carcelen M, Finer NN, et al Neurodevelopmental outcomes in the early CPAP and pulse oximetry trial. N Engl J Med. 2012;367:2495–2504.
48. Askie LM, Henderson-Smart DJ, Ko H. Restricted versus liberal oxygen
exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev. 2009;(1):CD001077.
49. Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation
target studies. Neonatology. 2014;105:55–63.
50. Manja V, Lakshminrusimha S, Cook DJ. Oxygen saturation
target range for extremely preterm infants: a systematic review and meta-analysis. JAMA Pediatr. 2015;169:332–340.
51. Tarnow-Mordi W, Stenson B, Kirby A, et al Outcomes of two trials of oxygen
-saturation targets in preterm infants. N Engl J Med. 2016;374:749–760.
52. Sola A, Golombek SG, Montes Bueno MT, et al Safe oxygen saturation
targeting and monitoring in preterm infants: can we avoid hypoxia
? Acta Paediatr. 2014;103:1009–1018.
53. Deulofeut R, Critz A, Adams-Chapman I, Sola A. Avoiding hyperoxia
in infants ≤250 g is associated with improved short- and long-term outcomes. J Perinatol. 2006;26:700–705.
54. Wright KW, Sami D, Thompson L, Ramanathan R, Joseph R, Farzavandi S. A physiologic reduced oxygen
protocol decreases the incidence of threshold retinopathy of prematurity
. Trans Am Ophthalmol Soc. 2006;104:78–84.
55. Birenbaum HJ, Dentry A, Cirelli J, et al Reduction in the incidence of chronic lung disease in very low birth weight infants: results of a quality improvement process in a tertiary level neonatal intensive care unit. Pediatrics. 2009;123:44–50.
56. Davidson D, Barefield ES, Kattwinkel J, et al Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group. Pediatrics. 1998;101:325–334.
57. Clark RH, Kueser TJ, Walker MW, et al Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. N Engl J Med. 2000;342:469–474.
58. Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure. The Neonatal Inhaled Nitric Oxide Study Group [published correction appears in N Engl J Med. 1997;337:434. N Engl J Med. 1997;336:597–604.
59. Steinhorn RH, Kinsella JP, Pierce C, et al Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009;155:841–847.
60. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006;117:1077–1083.
61. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr. 2002;141:830–832.
62. Bindl L, Fahnenstich H, Peukert U. Aerosolised prostacyclin for pulmonary hypertension in neonates. Arch Dis Child Fetal Neonatal Ed. 1994;71:F214–F216.
63. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med. 1997;23:1275–1278.
64. Olmsted K, Oluola O, Parthiban A, Raghuveer T. Can inhaled prostacyclin stimulate surfactant in ELBW infants? J Perinatol. 2007;27:724–726.
65. Galie N, Rubin L, Hoeper M, et al Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093–2100.
66. Humbert M, Barst RJ, Robbins IM, et al Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353–359.
67. Mohamed WA, Ismail M. A randomized, double-blind, placebo-controlled, prospective study of bosentan for the treatment of persistent pulmonary hypertension of the newborn. J Perinatol. 2012;32:608–613.
68. McNamara PJ, Shivananda SP, Sahni M, Freeman D, Taddio A. Pharmacology of milrinone in neonates with persistent pulmonary hypertension of the newborn and suboptimal response to inhaled nitric oxide. Pediatr Crit Care Med. 2013;14:74–84.